Magon, Stefano http://orcid.org/0000-0003-1517-7581
Tsagkas, Charidimos
Gaetano, Laura
Patel, Raihaan
Naegelin, Yvonne
Amann, Michael
Parmar, Katrin
Papadopoulou, Athina
Wuerfel, Jens
Stippich, Christoph
Kappos, Ludwig
Chakravarty, M. Mallar
Sprenger, Till
Article History
Received: 3 July 2019
Revised: 29 January 2020
Accepted: 31 January 2020
First Online: 10 February 2020
Compliance with ethical standards
:
: Charidimos Tsagkas, Chakravarty M. Mallar, Christoph Stippich, Amann Michael and Raihaan Patel have no disclosures. Naegelin Yvonne: Her employer, the University Hospital Basel received payments for lecturing from Celgene GmbH and Teva Pharma AG that were exclusively used for research support, not related to this study. K. Parmar: Her institution (University Hospital Basel) received speakers’ honoraria from Novartis and ExceMED and travel support by Novartis Switzerland. Laura Gaetano was a temporary employee of Novartis AG and she is currently an employee of F. Hoffmann-La Roche (her current institution was not involved in this project at any time). Athina Papadopoulou has received speaker-fee from Sanofi-Genzyme and travel support from Bayer AG, Teva, Roche and ECTRIMS. Her research was/is being supported by the University of Basel, the Swiss Multiple Sclerosis Society, the Swiss National Science Foundation and the “Stiftung zur Förderung der gastroenterologischen und allgemeinen klinischen Forschung sowie der medizinischen Bildauswertung”. J. Wuerfel: CEO of MIAC AG, Basel, Switzerland; speaker honoraria (Bayer, Biogen, Novartis, Teva); advisory boards and research grants (Biogen, Novartis); supported by the German Ministry of Science (BMBF/KKNMS) and German Ministry of Economy (BMWi). Ludwig Kappos’ institution (University Hospital Basel) has received research support and payments that were used exclusively for research support for Dr Kappos’ activities as principal investigator and member or chair of planning and steering committees or advisory boards in trials sponsored by Actelion, Addex, Almirall, Bayer HealthCare, Celgene, CLC Behring, Genentech, GeNeuro, Genzyme, Merck Serono, Mitsubishi Pharma, Novartis, Octapharma, Ono, Pfizer, Receptos, F. Hoffmann-La Roche, Sanofi- Aventis, Santhera, Siemens, Teva, UCB, and XenoPort; licence fees for Neurostatus 4 products; research grants from the Swiss Multple Sclerosis Society, the Swiss National Research Foundation, the European Union, and the Roche Research Foundation. The current (DKD Helios Klinik Wiesbaden) or previous (University Hospital Basel) institutions of Till Sprenger have received payments for speaking or consultation from: Biogen Idec, Eli Lilly, Allergan, Actelion, ATI, Mitsubishi Pharma, Novartis, Genzyme, and Teva. Dr. Sprenger received research grant s from the Swiss MS Society, Novartis Pharmaceuticals Switzerland, EFIC-Grünenthal grant, and Swiss National Science foundation. Stefano Magon is currently an employee of F. Hoffmann-La Roche (his current institution was not involved in this project at any time). He has received research support from Swiss Multiple Sclerosis Society, Swiss National Science Foundation, University of Basel and Stiftung zur Förderung der gastroenterologischen und allgemeinen klinischen Forschung sowie der medizinischen Bildauswertung University Hospital Basel.